SION Sionna Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 2036042 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-55.0%
TTM EPS YoY47.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-39.0%
ROA-36.4%
ROIC (approx.)-44.5%
Asset turnover—
Leverage & solvency
Liabilities / assets8.6%
Debt / equity0.00x
Current ratio13.92x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.73x
Accruals ratio-10.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $22.02M | $21.86M | $18.96M | $15.17M | $16.04M | $15.38M | $13.67M | $14.25M |
| SG&A expense | $12.79M | $10.61M | $10.64M | $8.44M | $7.76M | $6.52M | $5.99M | $3.88M |
| Operating income | -$34.82M | -$32.47M | -$29.60M | -$23.61M | -$23.80M | -$21.91M | -$19.66M | -$18.13M |
| Net income | -$32.42M | -$29.89M | -$26.78M | -$20.44M | -$20.28M | -$18.07M | -$16.48M | -$15.85M |
| EBITDA | -$34.62M | -$32.27M | -$29.45M | -$23.46M | -$23.70M | -$21.81M | -$19.50M | -$17.97M |
| EPS (basic) | -0.72 | -0.66 | -0.60 | — | -0.46 | -0.41 | -0.62 | — |
| EPS (diluted) | -0.72 | -0.66 | -0.60 | — | -0.46 | -0.41 | -0.62 | — |
| Weighted avg. shares (diluted) | 45.21M | 45.15M | 44.92M | — | 44.26M | 44.12M | 26.60M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $83.88M | $63.32M | $63.32M | $58.45M | $50.83M | $40.98M | $82.69M | $38.75M |
| Current assets | $228.53M | $216.13M | $220.96M | $241.42M | $252.33M | $266.75M | $273.68M | $150.99M |
| PP&E, net | $1.76M | $1.92M | $2.07M | $2.23M | $2.14M | $2.25M | $2.39M | $2.47M |
| Total assets | $263.26M | $283.25M | $305.04M | $325.95M | $339.27M | $352.05M | $369.67M | $185.75M |
| Current liabilities | $16.42M | $10.78M | $9.78M | $11.71M | $9.85M | $7.55M | $9.53M | $10.42M |
| Total liabilities | $22.74M | $17.47M | $16.83M | $19.12M | $17.60M | $15.62M | $17.91M | $19.10M |
| Shareholders' equity | $240.52M | $265.77M | $288.21M | $306.83M | $321.67M | $336.43M | $351.77M | -$163.71M |
| Shares outstanding | 45.21M | 45.16M | 45.08M | 44.72M | 44.46M | 44.13M | 44.09M | 4.72M |
| Cash flow statement | ||||||||
| Operating cash flow | -$18.72M | -$22.22M | -$21.84M | -$16.63M | -$15.23M | -$18.15M | -$16.29M | -$11.78M |
| Capital expenditure | $0 | $0 | $0 | $204,000 | $87,000 | $0 | $86,000 | $27,000 |
| Free cash flow | -$18.72M | -$22.22M | -$21.84M | -$16.83M | -$15.32M | -$18.15M | -$16.37M | -$11.81M |
| Investing cash flow | $38.95M | $21.47M | $24.82M | $22.59M | $23.10M | -$23.25M | -$141.19M | $15.23M |
| Financing cash flow | $333,000 | $749,000 | $1.89M | $1.66M | $1.97M | -$312,000 | $202.39M | -$1.41M |
| Depreciation & amortization | $200,000 | $200,000 | $154,000 | $152,000 | $100,000 | $100,000 | $159,000 | $167,000 |
| Stock-based compensation | $7.08M | $6.84M | $6.55M | $3.83M | $3.31M | $2.84M | $2.09M | $1.06M |
Free plan shows the latest 8 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.